Kornimate/medical-research-clean huggingface dataset:
will erectile dysfunction increase the risk of prostate cancer

Conditions: Erectile Dysfunction

Summary: the rationale for investigating the hypothesis that there is an association between erectile dysfunction (ed) and the subsequent development of prostate cancer is based on three assumptions: 1) baseline ed is common in most if not all of the cross-sectional studies in men with prostate cancer; 2) the development of ed and prostate cancer may have certain shared common risk factors; and 3) the use of testosterone for the treatment of ed has been suspected to be associated with prostate cancer development. controversy exists over whether men with ed have an increased risk of subsequent prostate cancer. few studies have evaluated the risk of developing prostate cancer for men with ed. the investigators, therefore, conducted a population-based longitudinal study with eight years' follow-up to examine this association and to evaluate the magnitude of the risk.


Eligibility criteria:
inclusion criteria: * men 50 years and older with no pre-existing prostate cancer exclusion criteria: * less than 50 years old * pre-existing prostate cancer

Keywords: cohort study prostate cancer population-based study benign prostatic hypertrophy
correlation of intramedullary pressure and systemic inflammatory parameters in cemented femoral stem

Conditions: Arthroplasty Complications

Summary: the cemented femoral stem have impact on increase on systemic parameters. evaluation of the level of histamine, c-reactive protein (crp) and leukocytes formula, il1b, tnf alpha, il6 and the reflection of changes of these parameters in the intra-operative course of hip replacement.

implantation of total endoprosthesis is a very common surgical procedure and is performed with and without bone cement. in most cases during cementation of the femoral component there are changes in blood pressure, spo2, heartbeat and other vital parameters which can cause complications during surgery. comparing the system parameters between the two groups and deriving these results will help the medical staff to be more professionally prepared to resolve possible complications.

Eligibility criteria:
inclusion criteria: the inclusion criteria were as follows: * all patients willing to participate who underwent cemented and uncemented tha, * with no limit on age exclusion criteria: the exclusion criteria were patients with: * periprosthetic fractures, * pathological fractures * tha revision * asa iv
efficacy and safety of snail slime and natural extracts for healing in diabetic foot ulcers

Conditions: Diabetic Foot Ulcer

Summary: the primary objective is to evaluate the efficacy and safety of the use of a formulation of snail slime and natural extracts, for the curative treatment of ulcer wonds in diabetic foot. the secondary objetives: 1. to evaluate the efficacy of the use of a formulation of snail slime helix aspersa müller and natural extracts (mu001) for the curative treatment of ulcer wonds in diabetic foot with respect to the standard of care, by means the application of patchs that containing the formulation in a treatment period of until 60 days. 2. to determine the safety of the use of a formulation of snail slime helix aspersa müller and natural extracts (mu001) in diabetic individuals in a treatment period of until 60 days.

clinical study of phase i-ii, controlled, simple blind (in relation with biostatistical analysis), randomized, of formulation that containing snail slime helix aspersa müller (cryptophalus aspersus), natural calendula extract, propolis and excipients (mu001). the formulation in study mu001 wil be added to the standard of care for healing in diabetic foot indicated. the period of recruitment estimated will be 4 month and the follow-up of the patients will be of until 60 days.

Eligibility criteria:
inclusion criteria: * diabetes type 2 * unilateral ulcers * grade 1 or grade 2 wagner ulcers. * without infection (except onychomycosis) * network family, hygiene, adherence and compliance appropiated exclusion criteria: * bilateral ulcers * medical conditions with high risk (cancer, allergies) * consum of abuse drugs
a pharmacokinetic and pharmacodynamic study of omecamtiv mecarbil in healthy volunteers

Conditions: Heart Failure

Summary: this study will assess the safety, tolerability, and pharmacodynamics of omecamtiv mecarbil infusion in healthy male volunteers.


Eligibility criteria:
inclusion criteria: 1. subject is male 2. subject is aged between 18 and 50 years inclusive. 3. subject has given signed informed consent. 4. subject's body mass index (bmi) is between 18 and 30 kg/m2 inclusive. 5. subject weighs less than 100 kg. 6. subject is considered to be in good health in the opinion of the investigator, as determined by: 1. a pre-study physical examination with no clinically significant abnormalities. 2. vital signs within normal ranges (supine after 3 minutes rest - heart rate: 40 to 80 bpm; systolic bp: 100 to 140 mmhg; diastolic bp: 50-90 mmhg; respiration rate: 8 to 18 breaths per minute; oxygen saturation: 96-100%) 3. an ecg with no clinically significant abnormalities. 7. subject's pre-study clinical laboratory findings are within normal range or if outside of the normal range not deemed clinically significant in the opinion of the investigator. 8. cardiac troponin i is less than the upper limit of the laboratory reference range. 9. a screening echocardiogram demonstrates normal cardiac function, an ejection fraction of between 40% and 70% with no significant valvular regurgitation (grade 1) and/or stenosis and images are deemed to be of good quality by the sonographer. exclusion criteria: 1. subject has had a clinically significant illness in the four weeks before screening. 2. use of prescribed mediations in the 3 weeks prior to dosing or over-the-counter preparations (including vitamin supplements and herbal remedies) for 7 days prior to dosing, except paracetamol which will be allowed up to 48 hours prior to dosing. 3. subject has a significant history of drug/solvent abuse or a positive drugs of abuse test at screening. 4. subject with a history of alcohol abuse or currently drinks in excess of 28 units per week. 5. subject smokes more than 5 cigarettes (or equivalent) per day. 6. subject is not willing to refrain from caffeine/xanthine containing products from 48 hours prior to the screening medical and admission on day -1 until the post study medical. 7. subject is in the opinion of the investigator not suitable to participate in the study. 8. subject who has participated in any clinical study with an investigational drug/device within three months prior to the first day of dosing. 9. subject who has a positive result of hiv screen, hepatitis b screen or hepatitis c screen. 10. subject has had a serious adverse reaction or significant hypersensitivity to any drug. 11. subject has donated 500 ml or more of blood within the month prior to screening. 12. subject has a history of cardiovascular disease or family history of premature cardiovascular disease or death.
intrathecal analgesia effects on cancer patients discomfort symptoms

Conditions: Refractory Cancer Pain; Intrathecal Analgesia

Summary: intrathecal analgesia is used in refractory cancer pain because of drug sides effects or intractable pain. the aim of this approach is to improve pain management, and also to improve patient comfort. this study will assess patient discomfort symptoms before and after setting up intrathecal analgesia.

descriptive multicenter study including patients with refractory cancer pain (unmanageable drug sides effects or intractable pain) who will receive intrathecal analgesia patient discomfort symptoms will be evaluated before and after the beginning of intrathecal analgesia at 15, 30, 60 and 90 days. moreover, the impact on patient close relatives and on return home will be assessed.

Eligibility criteria:
inclusion criteria: * patients aged 18 and older * obligation of affiliation or beneficiary of a social security scheme * patients with cancer and refractory localized cancer pain because of drug side effects or intractable pain * localized pain in topography accessible to intrathecal analgesia (legs, abdomen and pelvis, pancoast-tobias symdrom) * patient's informed consent for the study * patient able to complete the evaluation questionnaires * estimed vital prognosis more than three month * patient with all conditions for intrathecal anagelsia exclusion criteria: * patient with intracranial hypertension * refusal of patient to be included in the study * refusal of patient to receive intrathecal analgesia * patient with many refractory pain localizations not accessible to intrathecal analgesia

Keywords: refractory cancer pain intrathecal analgesia pain management discomfort symptoms management
new biopsy technique for uveal melanoma

Conditions: Uveal Melanoma

Summary: this pilot study intends to investigate a new biopsy technique that will decrease the incidence of tumor cells in the biopsy tract.

uveal melanoma is the most common primary malignancy of the eye and is one of the few fatal diseases that are detected initially through an eye examination. for many years, clinical decision-making regarding which patient with uveal melanoma required treatment has been based solely on clinical features observed at the time of diagnosis. these features include: tumor size as measured by ultrasound, associated subretinal fluid, presence of orange lipofuscin pigment, lack of drusen, posterior location, and ciliary body involvement. all of these clinical features have been demonstrated to be associated with tumor growth which is associated with the eventual development of metastases. however, these clinical features are not adequately sensitive or specific enough to predict which patients will develop metastases. more recently, researchers studying the genomics of uveal melanoma have focused on identifying genetic abnormalities present in tumor tissue in order to characterize these lesions more fully. several landmark papers over the past 15 years have reported cytogenic and genomic abnormalities in uveal melanoma tumor tissue that are associated with a poorer prognosis. although rare, there have been at least five cases in which patients undergoing biopsy of these lesions have developed extraocular spread of melanoma from the biopsy sites. with this new technique, the possible rate of extraocular spread should be lower, making the biopsy a safer technique than what is currently in practice.

Eligibility criteria:
inclusion criteria: * diagnosed with uveal melanoma * scheduled for enucleation surgery exclusion criteria: * patients under 21 years old * patients unable to undergo surgery * patients with known metastatic uveal melanoma or other cancer.

Keywords: uveal melanoma biopsy enucleation ocular cancer
prediction model of acute postoperative pain in bilateral total knee replacement arthroplasty patient

Conditions: Arthritis Knee; Anesthesia; Arthropathy of Knee

Summary: this study aims to predict risk factors of acute postoperative pain of the patients undergoing total knee replacement arthroplasty(tkra).

patients undergoing bilateral tkra are recruited. the time interval between the surgery of each leg is within 2 weeks. before each surgery, patients will be asked to conduct questionnaires of hospital anxiety and depression scale(hads) and pain catastrophizing scale(pcs). in addition, the patients will have their preoperative knee pain(measured by knee injury and osteoarthritis outcome score), preoperative pain in other sites, expectation of postoperative pain(measured by numerical rating scale), and morbidity of diabetic neuropathy recorded. demographic factors including age, sex, and bmi of patients will be collected. twenty four and forty eight hours after completion of the surgery, each patient will be asked to report thier acute postoperative pain on numerical rating scale. this study aims to find out risk factors of acute postoperative pain, including identical surgical history within 2 weeks, in patients undergoing bilateral tkra.

Eligibility criteria:
inclusion criteria: * 1) patients undergoing bilateral tkra with spinal anesthesia * 2) patients who have their second tkra in one leg within 2 weeks after their first tkra in the other leg. * 3) patients who are classified to the state of asa physical status classification system ⅰ,ⅱ, or ⅲ. exclusion criteria: * 1) patients incapable of communication

Keywords: tkra postoperative pain
trial of clopidogrel after surgery for coronary artery disease (cascade trial)

Conditions: Atherosclerosis

Summary: the purpose of this study is to determine whether the combination of clopidogrel with aspirin prevents the development of blockages (atherosclerosis) in vein grafts one year after coronary artery bypass surgery (cabg) compared to aspirin alone.

saphenous vein graft disease remains a major limitation of coronary artery bypass graft surgery (cabg). the process of saphenous vein intimal hyperplasia is mediated by platelet aggregation and begins just days after surgical revascularization. subsequently, areas of intimal hyperplasia in turn develop graft atherosclerotic disease and its sequelae. clopidogrel improves outcomes in patients with atherosclerotic disease, and is effective at reducing intimal hyperplasia in animal models of thrombosis. therefore, the goal of this study will be to evaluate the efficacy of clopidogrel and aspirin therapy versus aspirin alone in the prevention of saphenous vein graft intimal hyperplasia following one year after cabg. patients undergoing multi-vessel cabg and in whom at least two saphenous vein grafts will be used are eligible for the study. patients will be randomized to receive daily clopidogrel 75 mg or placebo, in addition to daily aspirin 162 mg, for the duration of one year starting as soon as postoperative bleeding has been ruled out on the day of surgery. at the end of one year, all patients will undergo coronary angiography and intravascular ultrasound assessment of one saphenous vein graft as selected by randomization. the study will be powered to test the hypothesis that clopidogrel and aspirin will reduce vein graft intimal hyperplasia by 20% compared to aspirin alone at one year following bypass surgery.

Eligibility criteria:
inclusion criteria: * patients undergoing primary multi-vessel cabg with at least two saphenous vein grafts, with or without the use of cardiopulmonary bypass. exclusion criteria: * emergency surgery * valve surgery * redo cabg * left ventricle ejection fraction \< 25% * serum creatinine \> 130 µmol/l * preoperative use of clopidogrel (with the exception of the current admission) * preoperative use of warfarin; allergy to aspirin or clopidogrel. * history of cerebrovascular accident * history of severe liver disease * morbid obesity * current malignancy

Keywords: saphenous vein intimal hyperplasia coronary artery bypass graft surgery antiplatelet therapy clopidogrel saphenous vein graft disease
effects of high-frequency repetitive transcranial magnetic stimulation on cerebral autoregulation in patients with cerebral small vessel disease

Conditions: Transcranial Magnetic Stimulation

Summary: the purpose of this study was to investigate the effect of high-frequency repetitive transcranial magnetic stimulation on cerebral autoregulation in patients with cerebral small vessel disease.

current studies have shown that repetitive transcranial magnetic stimulation can change the excitability of nerve cells, improve intracerebral artery blood supply, and even reduce the degree of neurological impairment in patients with stroke. the purpose of this study was to investigate the effect of high-frequency repetitive transcranial magnetic stimulation on cerebral autoregulation in patients with cerebral small vessel disease.

Eligibility criteria:
inclusion criteria: 1. age 18-80 years, regardless of gender; 2. diagnosed with csvd, and neuroimaging presented as recent small subcortical infarcts; 3. initiated transcranial magnetic stimulation within 7 days of onset; 4. subject or legal representative agreed to the treatment and signed the informed consent; exclusion criteria: 1. vascular stenosis \> 50% diagnosed by transcranial doppler (tcd) and carotid ultrasound; 2. previous history of atrial fibrillation or myocardial infarction within 6 months; 3. moyamoya disease or hereditary cerebral small vessel disease, such as cadasil; 4. white matter hyperintensities (wmh) of non-vascular origin; 5. severe hepatic and renal diseases, cancer or other major diseases related to integral medical and surgical procedures; 6. patients with contraindications to transcranial magnetic stimulation, such as metal or electronic devices in the brain; 7. pregnant or breastfeeding women; 8. the patients with disorders of consciousness, agitation or insufficient bilateral temporal bone windows for insonation who cannot cooperate to dynamic cerebral autoregulation monitoring; 9. previous history of epilepsy or family history of epilepsy; 10. previous treatment with transcranial magnetic stimulation or its equivalent; 11. unwillingness to be followed up or poor adherence to treatment; 12. those who are participating in other clinical investigators, or who have participated in other clinical studies within 3 months prior to enrollment, or who have participated in this study; 13. other conditions that the investigators deemed unsuitable for enrollment.
a study to assess the efficacy and safety of bismuth tripotassium dicitrate (de-nol) in combination with pantoprazole and pantoprazole monotherapy in treatment of subjects with nonsteroidal anti-inflammatory drugs (nsaid)-induced gastropathy

Conditions: NSAID-induced Gastropathy

Summary: the main purpose of this study is to evaluate clinical efficacy of bismuth tripotassium dicitrate (de-nol) in combination with pantoprazole versus pantoprazole monotherapy in subjects with nsaid-induced gastropathy in 14±2 days of treatment.

this study has a screening period (up to 3±2 days duration). randomization will be held in each stratum (h. pylori-positive and h. pylori-negative) on the visit 1. treatment period will consist of 2 visits: visit 2 (up to 14±2 days after visit 1) in subjects with completely healed ulcer(s) and erosions after control esophagogastroduodenoscopy (egds) and visit 3 (up to 28±2 days after visit 1) in subjects with not healed ulcers and erosions after control egds on visit 2. the period of follow-up safety assessments will last 1 week after the end of the study treatment

Eligibility criteria:
inclusion criteria: * verified diagnosis of nsaid-induced gastropathy: * presence of gastric ulcer(s) and/or erosions (modified lanza score greater than or equal to 5) based on egds findings at screening and; * nsaids administration within 7 days before screening. * negative pregnancy test at screening and at visit 1 (for females only using test strip to detect chorionic gonadotropin in urine), * subjects' consent to use a reliable contraception method starting from screening throughout the whole study and for 1 week after its termination. exclusion criteria: * severe complications of nsaid-gastropathy (bleedings, perforations, etc.) * the subjects requiring concomitant therapy using the drugs specified in "forbidden concomitant therapy". * ulcerative esophagitis grade c and higher according to los-angeles classification. * expressed hepatic and renal impairment. * any esophageal and gastric surgery that can make subject ineligible for study participation. * abuse of psychoactive substances including alcohol which may interfere with the subject's participation and fulfillment of all the protocol requirements. * participation in other clinical studies within 30 days prior to screening visit. * administration of bismuth products less than 2 months prior to screening. * administration of ppis or histamine н2-receptor antagonists less than 2 weeks prior to screening. * hypersensitivity to any of the components of the study drugs or contraindications to them. * pregnancy and lactation. * inability to perform follow-up egds after 2 and/or 4 weeks of the study. * any condition or concomitant disease and laboratory parameter abnormalities which renders the subject ineligible for the study.

Keywords: de-nol nsaid-induced gastropathy pantoprazole bismuth tripotassium dicitrate russia
autologous conditioned plasma (acp) for patients with plantar fasciitis

Conditions: Chronic Plantar Fasciitis

Summary: plantar fasciitis presents clinically as pain in the inner heal, which is the result of degeneration of the plantar fascia, an arch supporting ligament of the foot. it manifests predominantly in those subjected to sustained weight bearing or repetitive pounding activities. plantar fasciitis is the most common cause of inferior foot pain. although most cases resolving within 6 months, traditional treatment regiments such as orthotics and physiotherapy are occasionally unsuccessful in treating this limitation leading to chronic symptoms (neufeld \& cerrato, 2008; rompe, 2009; roxas, 2005). platelets are central players in clotting, inflammation and the wound healing response. research has shown the potential of platelet rich plasma to accelerate wound healing in a variety of conditions including maxillo-fascial and plastic surgery, chronic wound healing and orthopaedics. autologous conditioned plasma (acp) is a novel treatment that may accelerate the healing of injured tissue. treatment with acp involves taking a blood sample from the patient, isolating the platelets and injecting them back into that patient at the injury site


Eligibility criteria:
inclusion criteria: * painful inner heel pain for longer than three months * at least six weeks since last corticosteroid injection * four weeks since the last anaesthetic injection, iontophoresis, ultrasound and electromyostimulation * one week since the last nsaids taken * two days since the last analgesic, heat, ice, message, stretching, or modification of night splints and orthosis. * scores greater or equal to 5 on the vas pfpd scale * scores greater or equal 30 on the aofas scale * scores of greater or equal to 5 on the vas pfpd scale and 30 on the aofas scale exclusion criteria: * tendon rupture * neurological or vascular insufficiencies in the painful heel * bilateral heel pain * paget's disease or calcaneal fat pad atrophy * osteomyelitis, fracture of the calcaneus, ankle inflammation * recent infection in the treatment area, history of rheumatic diseases * collagenosis or metabolic disorders * immunosuppressive therapy or coagulation disturbance and/or therapy, long-term treatment with corticosteroids * previous heel surgery * malignant disease, diabetes mellitus, severe cardiac or respiratory disease, significant abnormalities in hepatic function * participation in another clinical study at the same time.

Keywords: plantar fasciitis autologous conditioned plasma
accuracy of pulse oximeters with profound hypoxia at rest

Conditions: Hypoxia

Summary: the aim of this study is to determine the accuracy of devices called pulse oximeters, which measure blood oxygen by shining light through fingers, ears or other skin, without requiring blood sampling. study will be used with patients at rest.

this study is intended to evaluate performance of a new design pulse oximeter (test device) manufactured by nihon kohden corporation sufficiently to support performance claims for an fda 510k submission or iso technical file. specifically, spo2 and pulse rate accuracy will be assessed for a nihon kohden olv-4202 pulse oximeter with adult patients under a controlled setting of varying levels of inhaled oxygen concentration levels for patients at rest.

Eligibility criteria:
inclusion criteria: * both male and female subjects who can give written informed consent * healthy subjects capable of undergoing controlled hypoxemia to the levels outlined in the desaturation profile * meeting the demographic requirements exclusion criteria: * age below 18 or over 50 * pregnant women * significant arrhythmia * blood pressure above 150 systolic or 90 diastolic * carboxyhemoglobin levels over 3% * subjects whom the investigator consider ineligible for the study